- My News
- All News
- Most Popular
According to Alyssa Watanabe, MD, FACR, chief medical officer at CureMetrix, "Improving sensitivity and specificity, cmAssist AI-CAD acts as a 'second pair of eyes' for the radiologist, delivering efficiency and more accurate detection of breast cancer for the women of Brazil."
"In 2020 there were over 66,000 new cases of breast cancer in Brazil. Empowering the radiologist with cmAssist can make a world of difference in flagging cancer earlier, with fewer false positives, so doctors can expedite care," said Navid Alipour, chief executive officer at CureMetrix. "We thank ANVISA for their review of cmAssist so we can continue to deliver the value that CureMetrix AI brings to women's health."
Details on cmAssist ANVISA registration information can be found at here at https://consultas.anvisa.gov.br/#/documentos/tecnicos/25351356579202146/25351356579202146/280509/
CureMetrix is also the creator of cmTriage™, also ANVISA approved and the first FDA-cleared AI-based triage solution for mammography in the U.S., which can be used by radiologists in tandem with cmAssist. cmTriage is a workflow optimization tool that prioritizes the mammography worklist, improving radiologist's productivity by up to 30 percent.
CureMetrix is a global leader in artificial intelligence (AI) for medical imaging, committed to the advancement of technology that improves disease detection and cancer survival rates worldwide. CureMetrix supports the radiologist to dramatically improve the accuracy of detection and the classification of anomalies in mammography exams and helps identify women at risk for heart disease. Our mission is to help save lives and support improved clinical and financial outcomes.
Did you like this article?